Результаты поиска

Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany.

IntroductionTo document the decision-making criteria physicians use when selecting regimens for second- and third-line therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) in Germany.MethodsExperienced multiple myeloma (MM) physicians extracted data from medical records from 30 June to 8 September 2023 for patients who initiated approved second- and third-line therapy for MM in 2021. Regimens, most important treatment goal, and key reasons for prescribing were reported in addition to patient characteristics. All data were summarised descriptively.ResultsMM physicians (3

Innovative Biomaterials for the Treatment of Bone Cancer.

Bone cancer is a demanding challenge for contemporary medicine due to its high frequency of presentation and significant heterogeneity of malignant lesions developing within the bone. To date, available treatments are rarely curative and are primarily aimed at prolonging patients' survival and ameliorating their quality of life. Furthermore, both pharmacological and surgical therapies are aggravated by a consistent burden of adverse events and subsequent disability due to the loss of healthy bone structural and functional properties. Therefore, great research efforts are being made to develop

Safety and efficacy studies of cross-unilateral, sequential unilateral, and bilateral percutaneous kyphoplasty for double-adjacent thoracolumbar osteoporotic vertebral compression fractures.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.

AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell clone that produces amyloidogenic light chains. Amyloid aggregates or preceding intermediaries cause direct cell damage through their proteotoxicity, and amyloid deposits distort tissue architecture, and, eventually, lead to organ impairment. It is a rare, underdiagnosed disease with a diverse clinical presentation depending on the organ tropism of the amyloid fibrils; cardiac and renal involvement is most common, but any organ can be affected, excluding the central nervous system. A high level of awaren

Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.

Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to achieve minimal residual disease (MRD) or complete response (CR) compared to patients with relapsed or refractory multiple myeloma. Response-based surrogate endpoints may hold value given the longer follow-up time required to evaluate PFS in NDMM. In this work, systematic literature reviews of Medline, Embase, and Cochrane databases (2010-06/2020) and relevant congresses (2018-2020) were performed to identify randomized cli

Управление неблагоприятными событиями, связанными с комбинациями на основе помалидомида у пациентов с повторной/редактируемой множественной миеломой.

Многоагентные режимы с иммуномодуляционными (IMID) агентами, такими, как палидомид, линалидомид и помалидомид, стали предпочтительным стандартом лечения пациентов с множественной миеломой (MM), что позволило улучшить показатели выживания. В настоящее время существуют three Агенты IMID, утвержденные для лечения MM: талидомид, линалидомид и помалидомид. Леналидомид обычно используется для лечения пациентов с недавно поставленным диагнозом MM, а также для лечения после пересадки стволовых клеток или после рецидива заболевания. Помалидомид, в центре внимания которого находится данный обзор, утверж

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Hematopoietic stem cell transplantation in Zagreb: the first 40 years.

Hematopoietic stem cell transplantation is the most effective treatment for acute leukemia, severe aplastic anemia, and some hereditary hematological disorders. The principal source of stem cells in this procedure are bone marrow and peripheral blood cells. In recent years, the transplantation outcome has significantly improved. The availability of the donor no longer poses a problem, as transplantation has been performed routinely from related, unrelated, and haploidentical donors. A high success rate has been reported in elderly patients transplanted with reduced-intensity conditioning. Impr

Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges.

Cancer continues to be the primary cause of death despite significant progress in medicine, and finding effective therapies remains a challenge. New treatments are needed to minimize the harmful effects on the body and increase the selectivity of drugs. These therapies must also overcome cancer cell resistance and prevent metastasis. Metal-based drugs are becoming increasingly crucial for treating tumors, and copper ion-based systems and nanoparticles have been identified as having unique properties and anticancer potential. Given the key role exerted by Cu in the etiology, severity, and progr

Kidney Transplant Outcomes of Patients With Multiple Myeloma.

IntroductionData on kidney transplantation (KTx) outcomes of patients with multiple myeloma (MM) are very limited.MethodsWe investigated the outcomes of patients with MM who underwent KTx between 1994 and 2019.ResultsA total of 12 transplants from 11 patients were included. At the time of KTx, 6 were classified as having stringent complete response (CR), 2 as CR, 2 as very good partial response (VGPR), and 2 as partial response (PR). With a median follow-up of 40 (minimum-maximum, 5-92) months after KTx, hematologic progression occurred in 9 transplants (75%). There were 3 grafts (25%) that fa

Psychometric evaluation of Oral Mucositis Daily Questionnaire: A cross-cultural adaptation of the Malay version in multiethnic adult autologous stem cell transplant.

ObjectiveMucositis is one of the most feared side effects of cancer treatment. Psychometric analysis of a patient self-assessment score, the oral mucositis daily questionnaire in Malay (OMDQ-Mal) and its construct validity by means of confirmatory factor analysis (CFA) is lacking. This research aimed to test the validity and reliability of OMDQ-Mal.MethodsA total of 114 autologous stem-cell transplantation patients aged ≥ 18 years old at a national hematology center in Malaysia from April 2019 to December 2020 completed OMDQ-Mal concurrently with physician scores. Internal consistency and repr

Новое определение "Моноклональной гаммопатии световой цепи" неизвестного значения.

ПОСЛЕДНИЕ ИССЛЕДОВАТЕЛЬСКИЕ ИССЛЕДОВАНИЯ говорят о том, что стандартные интервалы отсчета для бесперебойных световых цепочек (СВП) являются неточными и что эту проблему можно решить лишь частично путем использования отдельных интервалов отсчета для лиц с нарушенной функцией почек. Это снижает полезность тестирования FLC для клинической оценки и отслеживания расстройств плазменных клеток, особенно в том, что касается диагностики моноклонной гаммопатии световой цепи (LC) неопределенного значения (MGUS). ЦЕЛЬ: Оценить распределение соотношений сыворотки FLC и FLC у лиц с сохраненной функцией поче

NAPCON 2025 – Best Original Research Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).

Multiple myeloma (MM) is characterized by serial relapses, necessitating the application of sequential lines of therapy (LoT). Reports on attrition rates (ARs) vary widely. The present study analysed ARs from the Austrian Myeloma Registry. Attrition was defined as being either deceased, progressive without having received another LoT, or lack of follow-up for ≥5 years. A total of 571 patients diagnosed between January 2009 and August 2021 were included (median age: 72 years; median follow-up: 50.8 months). Some 507 patients received at least one LoT. Of the total, 43.6% underwent autologous st

Подтверждение того, что качество жизни, связанное со здоровьем, ухудшается для мониторинга долгосрочного прогресса в борьбе с заболеваниями, связанными с MS: продольный анализ из швейцарского регистра множественного склероза.

Мониторинг развития склероза (MS) традиционно опирается на клинические меры, которые могут игнорировать симптомы, влияющие на качество жизни. Включение результатов, сообщаемых пациентами, могло бы улучшить понимание ухудшения состояния заболеваний. ЦЕЛЬ: Оценить алгоритм на основе EQ-5D для обнаружения ухудшения болезни и сравнить его с ухудшением EDS. Мы проанализировали продольные данные EQ-5D и EDS из швейцарского регистра MS. Ухудшение состояния системы EQ-5D было определено как устойчивое сокращение по сравнению с двумя оценками; ухудшение состояния системы EDS осуществлялось в соответств

Совпадение в полном тексте источника
… Second, no established minimal clinically important difference (MCID) exists for changes of EQ‐5D in the context of MS progression. Third, EQ‐5D index values tend to change with increasing age (even in persons without MS), as well as with increasing disease‐duration. … We considered alternative worsening definitions for sensitivity analyses, including confirmed minimal clinically important differences (MCID) of 6, 8, 10, or 12‐point EQ‐5D index drops from baseline. Analyses were conducted using Stata SE Version 16.1 (Stata Corp., College Station, TX, USA). …

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Anticancer drugs should make patients live longer and/or feel better. Ideally, endpoints of cancer randomized controlled trials (RCT) should demonstrate that a drug leads to an increase in overall survival and/or improvement in quality of life. With the aim of including smaller numbers of patients, running shorter trials and thus getting new drugs to patients faster, cancer RCT are increasingly using (putative) surrogate endpoints. However, changes in surrogate endpoints often do not reliably predict improvements in overall survival and/or quality of life. Furthermore, especially in later line

Next-generation sequencing: advances and applications in cancer diagnosis.

Technological advances have led to the introduction of next-generation sequencing (NGS) platforms in cancer investigation. NGS allows massive parallel sequencing that affords maximal tumor genomic assessment. NGS approaches are different, and concern DNA and RNA analysis. DNA sequencing includes whole-genome, whole-exome, and targeted sequencing, which focuses on a selection of genes of interest for a specific disease. RNA sequencing facilitates the detection of alternative gene-spliced transcripts, posttranscriptional modifications, gene fusion, mutations/single-nucleotide polymorphisms, smal

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

BACKGROUND: Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti-CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2 trial (NCT03194867) was designed to determine whether cemiplimab (anti-PD-1) enhances the anti-myeloma activity of isatuximab (anti-CD38) in patients with relapsed and refractory multiple myeloma (RRMM), to confirm the feasibility of the combination, determine its efficacy, and further evaluate its safety. METHODS: Patients received isatuximab 10 mg/kg once weekly for 4 weeks f

Therapies and nanotherapies for cervical cancer (Review).

Cervical cancer (CC) is a major global health concern, ranking fourth worldwide in mortality, due to its high death rate and strong link to persistent high-risk human papillomavirus infections, which drive cancer progression through cellular dysregulation. Conventional therapies used in the treatment of CC have significant disadvantages, such as adverse side effects that affect the quality of life of patients. These side effects may include nausea, vomiting, fatigue, hair loss, fertility problems, damage to nearby organs and systemic toxicity. To address these challenges, there has been an inc

Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.

Bone metastases are a major concern in cancer management since they significantly contribute to morbidity and mortality. Metastatic lesions, commonly arising from breast, prostate, lung, and kidney cancers, affect approximately 25% of cancer patients, leading to severe complications such as pain, fractures, and neurological deficits. This narrative review explores contemporary approaches to bone metastases, emphasizing a multidisciplinary strategy and the evolving concept of oligometastatic disease. Oligometastases, defined by limited metastatic spread (1-5 lesions), offer a potential window f